Literature DB >> 26464702

Immunohistochemistry of p53 and Ki-67 and p53 mutation analysis in renal epithelioid angiomyolipoma.

Wenbin Li1, Lei Guo1, Xingang Bi2, Jianhui Ma2, Shan Zheng1.   

Abstract

BACKGOUND: Renal epithelioid angiomyolipoma (EAML) is a rare variant of AML (angiomyolipoma) and is often associated with aggressive behaviors. The pathogenesis of EAML has been poorly understood. We analyzed the expression of p53 and Ki-67 by immunohistochemistry (IHC) and investigated p53 mutation analysis in 11 cases of EAML in comparison to classical AML.
METHODS: P53 and Ki-67 expression status were determined by IHC staining. P53 mutation analysis was performed using bi-directional sequencing.
RESULTS: Renal EAML tumors were significantly associated with more severe to moderate nuclear atypia (100% vs. 36.4%, P = 0.004) and mitotic activity (90.9% vs. 27.3%, P = 0.008) compared with AML tumors. Out of 11 cases of EAML, 8 were positive for p53. There was only 1 case with positive p53 expression in AML cases and expression of p53 protein showed significant difference between EAML and AML tumors (72.7% vs. 9.1%, P = 0.008). In addition, there were 7 AML and 6 EAML cases harbored P72R mutation (SNP) in exon 4 of p53. Compared with AML cases, 2 out of 11 cases of EMAL showed more than 10% positivity for ki-67. The finding of stronger p53 expression in renal EAML might have contributed to their malignant behavior. However, the abnormal p53 expression cannot be entirely explained by p53 mutations in the exons examined.
CONCLUSIONS: Thus, the combination of immunohistochemical assessment of tumor antigens might improve our ability to predict the malignant outcome in EAML.

Entities:  

Keywords:  EAML; Ki-67; immunohistochemistry; mutation analysis; p53

Mesh:

Substances:

Year:  2015        PMID: 26464702      PMCID: PMC4583934     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  29 in total

1.  Epithelioid angiomyolipoma of the kidney mimicking renal sarcoma.

Authors:  E C Belanger; P K Dhamanaskar; K T Mai
Journal:  Histopathology       Date:  2005-10       Impact factor: 5.087

2.  p53 codon 72 polymorphism and the risk of lung cancer in a Korean population.

Authors:  Jin-Mei Piao; Hee Nam Kim; Hye-Rim Song; Sun-Seog Kweon; Jin-Su Choi; Woo-Jun Yun; Young-Chul Kim; In-Jae Oh; Kyu-Sik Kim; Min-Ho Shin
Journal:  Lung Cancer       Date:  2011-02-11       Impact factor: 5.705

3.  Role of p53 codon 72 polymorphism in the risk of development of distal gastric cancer.

Authors:  Guillermo Ignacio Pérez-Pérez; Francisco Javier Bosques-Padilla; Maria Luisa Crosatti; Rolando Tijerina-Menchaca; Elvira Garza-González
Journal:  Scand J Gastroenterol       Date:  2005-01       Impact factor: 2.423

4.  p53 codon 72 polymorphism as a risk factor in the development of breast cancer.

Authors:  E N Papadakis; D N Dokianakis; D A Spandidos
Journal:  Mol Cell Biol Res Commun       Date:  2000-06

5.  Infrequent alteration of p53 pathway in metastatic renal cell carcinoma.

Authors:  T Kawasaki; V Bilim; K Takahashi; Y Tomita
Journal:  Oncol Rep       Date:  1999 Mar-Apr       Impact factor: 3.906

6.  p53 regulation and function in renal cell carcinoma.

Authors:  Hazel E Warburton; Mark Brady; Nikolina Vlatković; W Marston Linehan; Keith Parsons; Mark T Boyd
Journal:  Cancer Res       Date:  2005-08-01       Impact factor: 12.701

Review 7.  The genetics of the p53 pathway, apoptosis and cancer therapy.

Authors:  Alexei Vazquez; Elisabeth E Bond; Arnold J Levine; Gareth L Bond
Journal:  Nat Rev Drug Discov       Date:  2008-12       Impact factor: 84.694

8.  TP53 mutations and survival in squamous-cell carcinoma of the head and neck.

Authors:  M Luana Poeta; Judith Manola; Meredith A Goldwasser; Arlene Forastiere; Nicole Benoit; Joseph A Califano; John A Ridge; Jarrard Goodwin; Daniel Kenady; John Saunders; William Westra; David Sidransky; Wayne M Koch
Journal:  N Engl J Med       Date:  2007-12-20       Impact factor: 91.245

9.  Malignant epithelioid angiomyolipoma of the kidney in a patient with tuberous sclerosis: an autopsy case report with p53 gene mutation analysis.

Authors:  Katsuaki Sato; Yoshimichi Ueda; Hiromichi Tachibana; Katsuhito Miyazawa; Ippei Chikazawa; Sachiko Kaji; Takayuki Nojima; Shogo Katsuda
Journal:  Pathol Res Pract       Date:  2008-06-10       Impact factor: 3.250

10.  The use of the Ki-67 marker in the pathological diagnosis of the epithelioid variant of renal angiomyolipoma.

Authors:  Sue Min Ooi; Justin B Vivian; Ronald J Cohen
Journal:  Int Urol Nephrol       Date:  2008-10-07       Impact factor: 2.370

View more
  8 in total

1.  Renal cell carcinoma: the search for a reliable biomarker.

Authors:  Nicholas J Farber; Christopher J Kim; Parth K Modi; Jane D Hon; Evita T Sadimin; Eric A Singer
Journal:  Transl Cancer Res       Date:  2017-06       Impact factor: 1.241

2.  Evaluation of ABO blood groups and blood-based biomarkers as a predictor of growth kinetics of renal angiomyolipoma.

Authors:  Burak Arslan; Okan Gürkan; Bugra Çetin; Öykü Aksoy Arslan; Taha Göv; Gökhan Yazıcı; Tolga Eroglu; Mustafa Asım Avcı; Enver Ozdemir
Journal:  Int Urol Nephrol       Date:  2018-10-15       Impact factor: 2.370

3.  Distinct subcellular localization of E-cadherin between epithelioid angiomyolipoma and triphasic angiomyolipoma: A preliminary case-control study.

Authors:  Xin-Gang Bi; Lei Guo; Xiao-Liang Wang; Qian Wei; Qiang Du; Wen-Hao Jiang; Guang-Yuan Zheng; Hong-Tu Zhang; Jian-Hui Ma; Shan Zheng
Journal:  Oncol Lett       Date:  2017-05-29       Impact factor: 2.967

4.  A rare highly aggressive tumor of the kidney: The pure epithelioid angiomyolipoma.

Authors:  Mohamed Amine Bani; Besma Laabidi; Sarra Ben Rejeb; Ramzi Khiari; Ammar Bouziani; Issam Msakni
Journal:  Urol Case Rep       Date:  2018-03-13

Review 5.  The Risks of Renal Angiomyolipoma: Reviewing the Evidence.

Authors:  Raouf M Seyam; Waleed K Alkhudair; Said A Kattan; Mohamed F Alotaibi; Hassan M Alzahrani; Waleed M Altaweel
Journal:  J Kidney Cancer VHL       Date:  2017-10-16

6.  A tissue-bioengineering strategy for modeling rare human kidney diseases in vivo.

Authors:  J O R Hernandez; X Wang; M Vazquez-Segoviano; M Lopez-Marfil; M F Sobral-Reyes; A Moran-Horowich; M Sundberg; D O Lopez-Cantu; C K Probst; G U Ruiz-Esparza; K Giannikou; R Abdi; E P Henske; D J Kwiatkowski; M Sahin; D R Lemos
Journal:  Nat Commun       Date:  2021-11-11       Impact factor: 17.694

7.  ♣Evaluation of clinicopathological profiles and development of a risk model in renal epithelioid angiomyolipoma patients: a large-scale retrospective cohort study.

Authors:  Aihetaimujiang Anwaier; Wen-Hao Xu; Xi Tian; Tao Ding; Jia-Qi Su; Yue Wang; Yuan-Yuan Qu; Hai-Liang Zhang; Ding-Wei Ye
Journal:  BMC Urol       Date:  2022-09-12       Impact factor: 2.090

8.  Coexistence of pulmonary lymphangioleiomyomatosis and pulmonary angiomyolipoma.

Authors:  Xuefeng Sun; Ruie Feng; Ye Zhang; Juhong Shi; Kai-Feng Xu
Journal:  BMC Pulm Med       Date:  2016-08-15       Impact factor: 3.317

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.